RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Edwards Lifesciences P/E 2024

Edwards Lifesciences P/E

31.84

Edwards Lifesciences Dividend yield

Ticker

EW

ISIN

US28176E1082

WKN

936853

As of Apr 16, 2024, Edwards Lifesciences's P/E ratio was 31.84, a -14.04% change from the 37.04 P/E ratio recorded in the previous year.

The Edwards Lifesciences P/E history

Edwards Lifesciences Aktienanalyse

What does Edwards Lifesciences do?

Edwards Lifesciences Corp is a globally operating company in the field of medical technology, specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. The company was founded in California in 1958 and is now one of the leading companies in the field of modern heart valve technology. The history of Edwards Lifesciences begins with its founding by Miles "Lowell" Edwards and his longtime employee Dr. Albert Starr. They recognized the need for a less invasive and more effective alternative to heart valves than the existing surgical methods. They received their first patent in 1960 and performed their first successful heart valve operation on a sheep in the same year. The first surgeries on humans took place in 1962. Edwards Lifesciences quickly expanded in the US and internationally. The business model of Edwards Lifesciences focuses on three business areas: "Transcatheter Heart Valve Systems," "Surgical Heart Valve Therapy," and "Critical Care." Each area is focused on a specific range of products and is supported by its own team of professionals. The "Transcatheter Heart Valve Systems" area has become the most important division of Edwards Lifesciences. This novel technology enables the implantation of an artificial heart valve system through minimally invasive surgical methods, without the need for an open procedure. The system consists of a foldable heart valve made of animal tissue or artificial material, which is inserted into the damaged heart through a catheter. This method is applicable to a wide range of patients and has become an important tool in the treatment of heart diseases. The "Surgical Heart Valve Therapy" business area includes implantable mechanical and biological heart valves for open surgical procedures. Edwards Lifesciences develops innovative products to meet the needs of surgical patients and doctors. The third business area, "Critical Care," offers instruments and technologies for the critical medical care of patients in intensive care units and emergency departments. The company manufactures collagen matrix products for wound care, catheter monitoring systems, and patient monitoring devices to detect potential life-threatening complications early. Over the years, Edwards Lifesciences has introduced numerous innovative products to the market that are used in medical practice. The Edwards SAPIEN Transcatheter Heart Valve System was approved in Europe in 2011 and in the US in 2012 and has since improved the lives of tens of thousands of patients. With new technologies such as the Edwards SAPIEN 3 and SAPIEN 3 Ultra platforms, the company is constantly striving to increase the effectiveness and safety of heart disease treatment. Edwards Lifesciences is headquartered in Irvine, California, and is a multinational company with locations in North America, Europe, India, and Asia. The company currently employs approximately 14,000 people worldwide and is an important pillar of the medical community. Answer: Edwards Lifesciences Corp is a global medical technology company specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. It is a leader in modern heart valve technology. Edwards Lifesciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Edwards Lifesciences's P/E Ratio

The Price to Earnings (P/E) Ratio of Edwards Lifesciences is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Edwards Lifesciences's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Edwards Lifesciences is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Edwards Lifesciences’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Edwards Lifesciences Stock

What is the price-to-earnings ratio of Edwards Lifesciences?

The price-earnings ratio of Edwards Lifesciences is currently 31.84.

How has the price-earnings ratio of Edwards Lifesciences changed compared to last year?

The price-to-earnings ratio of Edwards Lifesciences has increased by -14.04% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Edwards Lifesciences high compared to other companies?

Yes, the price-to-earnings ratio of Edwards Lifesciences is high compared to other companies.

How does an increase in the price-earnings ratio of Edwards Lifesciences affect the company?

An increase in the price-earnings ratio of Edwards Lifesciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Edwards Lifesciences affect the company?

A decrease in the price-earnings ratio of Edwards Lifesciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Edwards Lifesciences?

Some factors that influence the price-earnings ratio of Edwards Lifesciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Edwards Lifesciences pay?

Over the past 12 months, Edwards Lifesciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Edwards Lifesciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Edwards Lifesciences?

The current dividend yield of Edwards Lifesciences is .

When does Edwards Lifesciences pay dividends?

Edwards Lifesciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Edwards Lifesciences?

Edwards Lifesciences paid dividends every year for the past 0 years.

What is the dividend of Edwards Lifesciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Edwards Lifesciences located?

Edwards Lifesciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Edwards Lifesciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Edwards Lifesciences from 4/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/16/2024.

When did Edwards Lifesciences pay the last dividend?

The last dividend was paid out on 4/16/2024.

What was the dividend of Edwards Lifesciences in the year 2023?

In the year 2023, Edwards Lifesciences distributed 0 USD as dividends.

In which currency does Edwards Lifesciences pay out the dividend?

The dividends of Edwards Lifesciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Edwards Lifesciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Edwards Lifesciences

Our stock analysis for Edwards Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Edwards Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.